So Guys PLEASE READ CAREFULLY & UNDERSTAND THE MATTER

To avail the paid services of our group , everyone needs to do the following set of activities :

1) Everyone needs to fill in the Google Forms with the correct and accueate details.The form needs to be read carefully and then give upon your consent.

2)Pay us the fees of Rs.1000 each month either through Google Pay or Bank Transfers(details of payment are attached in the Google Form)

3) Upon completion of payment , take a screenshot of the acknowledgement and send it to us.It can be sent to the admin on the following numbers on the WhatsApp or Telegram :

Jimit Parekh Sir : +91 9821722433
Darpan Solanki Sir : +91 9924832776
Divesh Jain Sir: +91 9870736813

Along with the screenshot pls give us your NAME & Mobile Number to confirm with our Google Form Records.

PLS NOTE : STRICTLY ONLY MESSAGES , NO CALLS ON THE GIVEN NUMBERS.


https://docs.google.com/forms/d/e/1FAIpQLSed5g8JiIGlttu3IUlkJwnCdEMzv-1Z_hr3ylfU55pepmCb6A/viewform?usp=sf_link

Books - Make India Read
Our only aim is to make India Financially Literate. We are doing this service for free and don't have any monetary aim behind it.
https://t.me/BooksMakeIndiaRead

Dear All,

Nirmal Bang is inviting you to a Zoom webinar.
When: Jun 18, 2021 08:45 AM India
Topic: Morning Market Update

Register in advance for this webinar:
https://us02web.zoom.us/webinar/register/WN_J4uP0jJOQ8ySggQNO30Ipg


After registering, you will receive a confirmation email containing information about joining the webinar.

PHARMEASY IS LIKELY IN TALKS FOR STAKE BUY IN THYROCARE WITH THE DEAL INCLUDING A VELUMANI INVESTING IN PHARMEASY’S OWNER API HOLDINGS - CNBC TV 18

*DB Corp Ltd.* | *CMP* Rs. 113 | *M Cap* Rs. 1977 Cr | *52 W H/L* 113/58
(Nirmal Bang Retail Research)
*Result has improved*
Revenue from Operations came at Rs. 456.6 Cr (-7.6% QoQ, -6.2% YoY) vs QoQ Rs. 494.3 Cr, YoY Rs. 486.7 Cr
EBIDTA came at Rs. 101 Cr (-39% QoQ, 53.2% YoY) vs QoQ Rs. 165.6 Cr, YoY Rs. 65.9 Cr
EBITDA Margin came at 22.1% vs QoQ 33.5%, YoY 13.6%
Adj. PAT came at Rs. 61.9 Cr vs QoQ Rs. 99 Cr, YoY Rs. 24.1 Cr
Quarter EPS is Rs. 3.5
Share is trading at P/E of 8.2x FY22E EPS

https://youtu.be/IaBq486Rr6I

For more such interesting market insights, please subscribe to Nirmal Bang's YouTube channel.

HIMADRI SPECIALITY: CO CLRIFIES ON NEWS ITEM - “HSCL LIKELY TO ANNOUNCE STRATEGIC TIE UP WITH TESLA FOR BATTERIES” || CO SAYS CO IS IN NO SUCH DISCUSSIONS FOR ANY TIE UP WITH TESLA

*Power Mech Projects Ltd.* | *CMP* Rs. 710 | *M Cap* Rs. 1044 Cr | *52 W H/L* 726/354
(Nirmal Bang Retail Research)
*Result ok*
Revenue from Operations came at Rs. 755.2 Cr (48.5% QoQ, 27% YoY) vs QoQ Rs. 508.5 Cr, YoY Rs. 594.6 Cr
EBIDTA came at Rs. 74.5 Cr (238.4% QoQ, 14.5% YoY) vs QoQ Rs. 22 Cr, YoY Rs. 65.1 Cr
EBITDA Margin came at 9.9% vs QoQ 4.3%, YoY 11%
Adj. PAT came at Rs. 35.7 Cr vs QoQ Rs. 3.1 Cr, YoY Rs. 31.4 Cr
Quarter EPS is Rs. 24.2
Share is trading at P/E of 7.9x FY22E EPS

Daily Market Highlights | 17th Jun 2021 📊

NIFTY50: ₹15,691.40 | -0.48%

Top Gainers 📈

ULTRACEMCO: +1.69%
TCS: +1.64%
INFY: +1.39%
ASIANTPAINT: +1.36%
TECHM: +1.30%

Top losers 📉

ADANIPORTS: -8.99%
HINDALCO: -2.96%
INDUSINDBK: -2.96%
EICHERMOT: -2.63%
NTPC: -2.34%

Adani Group shares: Gautam Adani needs investors who have a website at least - The Economic Times - https://m.economictimes.com/markets/stocks/news/gautam-adani-needs-investors-who-have-a-website-at-least/articleshow/83593197.cms?utm_source=whatsapp_pwa&utm_medium=social&utm_campaign=socialsharebuttons

Follow this link to join my WhatsApp group: https://chat.whatsapp.com/KW2rP1KPs7TJw30A5BP4gL

*Fund Houses Recommendations*


CLSA on *HCL Tech*: Maintains Buy on company, target price at Rs 1160/Sh (Positive)

CLSA on *Lemon Tree*: Maintains Buy on company, target price at Rs 50/Sh (Positive)

Nomura on *Glenmark*: Maintains Buy on company, raise target price at Rs 762/Sh (Positive)

Nomura on *LIC Housing*: Maintains Buy on company, raise target price at Rs 625/Sh (Positive)

Jefferies on *Tata Steel*: Maintains Buy on company, target price at Rs 1500/Sh (Positive)

CLSA on *Tata Steel*: Maintains Buy on company, target price at Rs 1362/Sh (Positive)

Macquarie on *KEC*: Maintains Outperform on company, target price at Rs 490/Sh (Positive)

HSBC on *Indigo*: Maintains reduce on company, target price at Rs 1315/Sh (Neutral)

Exclusive | PharmEasy in talks to buy Thyrocare in deal worth around Rs 7,000 crore

https://www.moneycontrol.com/news/business/pharmeasy-in-talks-to-buy-thyrocare-in-deal-worth-around-rs-7000-crore-7048701.html

HIMADRI SPECIALITY: CO CLRIFIES ON NEWS ITEM - “HSCL LIKELY TO ANNOUNCE STRATEGIC TIE UP WITH TESLA FOR BATTERIES” || *CO SAYS CO IS IN NO SUCH DISCUSSIONS FOR ANY TIE UP WITH TESLA*

Securities in Ban For Trade Date 18-June-2021:

ADANIPORTS
BHEL
CANBANK
ESCORT
PNB

*Added No*
*Deleted NATIONALUM*

Lupin gets USFDA nod for Sevelamer tablets used for treatment of kidney disease - https://www.livemint.com/companies/news/lupin-gets-usfda-nod-for-sevelamer-tablets-used-for-treatment-of-kidney-disease-11623924898745.html


Download mint app for latest in Business News - https://bit.ly/32XEfFE

Exclusive | PharmEasy in talks to buy Thyrocare for around Rs 7,000 crore

https://www.moneycontrol.com/news/business/pharmeasy-in-talks-to-buy-thyrocare-in-deal-worth-around-rs-7000-crore-7048701.html

Download moneycontrol app: http://m.moneycontrol.com/mom

VENUS REMEDIES LTD: CO A RESEARCH AND DEVELOPMENT-DRIVEN PHARMACEUTICAL MANUFACTURING COMPANY THURSDAY WON A 10-YEAR LONG LEGAL BATTLE THAT CHALLENGED PATENT CLAIMED BY FRENCH PHARMACEUTICAL FIRM SCR PHARMATOP - MINT